Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 8, Issue 19

October 8 2024

In Progress

In this Issue

MYELOID NEOPLASIA
Lymphoid Neoplasia
CLINICAL TRIALS AND OBSERVATIONS
Plasma Cell Disorders
THROMBOSIS AND HEMOSTASIS
RESEARCH LETTER

MYELOID NEOPLASIA

Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

Valentina R. Minciacchi,Christina Karantanou,Jimena Bravo,Raquel S. Pereira,Costanza Zanetti,Theresa Krack,Rahul Kumar,Katrin Bankov,Sylvia Hartmann,Brian J. P. Huntly,Eshwar Meduri,Wolfram Ruf,Daniela S. Krause

View Articletitled, Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

Supplemental data

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Binod Dhakal,Hermann Einsele,Jordan M. Schecter,William Deraedt,Nikoletta Lendvai,Ana Slaughter,Carolina Lonardi,Sandhya Nair,Jianming He,Akshay Kharat,Patricia Cost,Satish Valluri,Kwee Yong

View Articletitled, Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Supplemental data

Lymphoid Neoplasia

A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL

Philip Gebing,Stefanos Loizou,Sebastian Hänsch,Julian Schliehe-Diecks,Lea Spory,Pawel Stachura,Vera H. Jepsen,Melina Vogt,Aleksandra A. Pandyra,Herui Wang,Zhengping Zhuang,Johannes Zimmermann,Martin Schrappe,Gunnar Cario,Ameera Alsadeq,Denis M. Schewe,Arndt Borkhardt,Lennart Lenk,Ute Fischer,Sanil Bhatia

View Articletitled, A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Meletios A. Dimopoulos,Daniel Coriu,Sosana Delimpasi,Ivan Špička,Terry Upchurch,Belle Fang,Rakhshandra Talpur,Edward Faber,Meral Beksac,Xavier Leleu

View Articletitled, A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Supplemental data

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Clinical Trials & Observations

Peter Voorhees,Vera Suman,Yvonne Efebera,Noopur Raje,Sascha Tuchman,Cesar Rodriguez,Jacob Laubach,Misty Bova-Solem,Destin Carlisle,Saad Usmani,Philip McCarthy,Paul G. Richardson

View Articletitled, Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse

Supplemental data

Plasma Cell Disorders

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma

Jiasi Zhang,Yuxi Liu,Liping Zuo,Fengjuan Fan,Han Yan,Fei Zhao,Junying Li,Chi Ma,Qun Li,Aoshuang Xu,Jian Xu,Bo Zhang,Yu Hu,Chunyan Sun

View Articletitled, Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma

Supplemental data

THROMBOSIS AND HEMOSTASIS

Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Crystal L. Perry,Pamela A. Christopherson,Tina A. Agostini,Sandra L. Haberichter,Robert R. Montgomery,Veronica H. Flood

View Articletitled, Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

Yaqiu Sang,Robert H. Lee,Annie Luong,Éva Katona,Claire S. Whyte,Nicholas L. Smith,Alan E. Mast,Matthew J. Flick,Nicola J. Mutch,Wolfgang Bergmeier,Alisa S. Wolberg

View Articletitled, Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

Supplemental data

RESEARCH LETTER

Histiocytosis of the orbit and its association with KRAS mutations

Jasmine H. Francis,Rebecca F. Silverman,Julia Canestraro,Dana Bossert,David Della Rocca,Vaios Hatzoglou,David H. Abramson,Eli L. Diamond

View Articletitled, Histiocytosis of the orbit and its association with <em>KRAS</em> mutations

Supplemental data

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Histiocytosis of the orbit and its association with KRAS mutations

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse

Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

Advertisement intended for health care professionals

MYELOID NEOPLASIA

Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Lymphoid Neoplasia

A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL

CLINICAL TRIALS AND OBSERVATIONS

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Clinical Trials & Observations

Plasma Cell Disorders

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma

THROMBOSIS AND HEMOSTASIS

Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

RESEARCH LETTER

Histiocytosis of the orbit and its association with KRAS mutations

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

MYELOID NEOPLASIA

Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Lymphoid Neoplasia

A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL

CLINICAL TRIALS AND OBSERVATIONS

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma Clinical Trials & Observations

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse Clinical Trials & Observations

Plasma Cell Disorders

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma

THROMBOSIS AND HEMOSTASIS

Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

RESEARCH LETTER

Histiocytosis of the orbit and its association with KRAS mutations

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Clinical Trials & Observations

Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Clinical Trials & Observations